AbbVie

Pharmaceuticals
ABBV
$ 155 (0.44)%
Share price
$ 274 bn
Market Cap
$ 328 bn
Enterprise Value

Carbon footprint

1.6 Ton
GHG emissions per $ 1 mln investment
0.06x the weighted average for S&P 500
FY2020
How is this calculated?
-10%
YOY change in GHG emissions
Stronger than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-2.4%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

AbbVie aims to reduce Scope 1 + 2 by 50% by 2035 from a base year 2015


This target has not been verified as science based according to SBTi
AbbVie's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

AbbVie's GHG emissions (market-based) (Kt of CO2e)
AbbVie's Carbon intensity (Tons per 1 USDm)

AbbVie's carbon footprint

AbbVie reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 508 Kt (-57 /-10.1% y-o-y). Also positively, carbon intensity fell to 11 t (-5.9 /-34.7% y-o-y).

No public disclosure of Scope 3 emissions has been found for AbbVie at the moment.

The company is committed to reducing Scope 1 + 2 by 50% by 2035 from a base year 2015, which translates into the estimated reduction of -12 Kt per annum over the period of FY2021 - FY2035. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...
Copyright © 2022 Exerica. All rights reserved.